Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30587342 | 0.83 | KDM4E (0.47) | TSHRPTGS1TDP1KDM4EALDH1A1 | |
| SCHEMBL29058037 | 0.83 | KDM4E (0.47) | TSHRPTGS1TDP1KDM4EALDH1A1 | |
| SCHEMBL10536230 | 0.82 | PTGS1 (0.62) | TSHRPTGS1TNFSF11NR3C1JUN | |
| SCHEMBL286388 | 0.82 | ALDH1A1 (0.43) | TSHRPTGS1TNFSF11NR3C1MAPT | |
| SCHEMBL6971645 | 0.81 | TSHR (0.45) | TSHRPTGS1TNFSF11NR3C1JUN | |
| SCHEMBL151821 | 0.81 | TSHR (0.55) | TSHRPTGS1TNFSF11NR3C1JUN | |
| SCHEMBL18475471 | 0.81 | PTGS2 (0.46) | TSHRMAPTTDP1TUBB1KDM4E | |
| SCHEMBL29695219 | 0.76 | MAPT (0.36) | MAPTTDP1ALDH1A1GAA | |
| SCHEMBL3782773 | 0.76 | MAPT (0.62) | TSHRMAPTTDP1TUBB1KDM4E | |
| SCHEMBL27496747 | 0.76 | PTGS2 (0.50) | TSHRPTGS1TDP1PTPN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569317-B2 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-7696216-B2 | Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20100063075-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | ALTMANN EVA | 2010-03-11 | — | — | US | disclosed |
| EP-1585521-B8 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| EP-1585521-B1 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1844780-A2 | Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone | Novartis Pharma AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2006-04-13 | — | — | US | disclosed |
| EP-1585521-A2 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004056365-A2 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | TSHR 247/4885PTGS1 1683/4885TNFSF11 2799/4885 |
| US-20100063075-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | TSHR 252/4885PTGS1 1589/4885TNFSF11 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.